Hosted by Dr. Cush · EN
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com

Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikuls Moderator: Dr. Jack Cush
Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com

This webinar explores the evolving role of imaging in the diagnosis and management of gout. Our expert panel will discuss when and how to use ultrasound, dual-energy CT (DECT), crystal identification, and conventional radiography, while addressing practical questions such as the role of imaging in diagnostic uncertainty, serial disease monitoring, and whether ultrasound is changing the need for synovial fluid analysis in everyday practice. Panelists: Dr. Nicola Dalbeth Dr. John Fitzgerald Dr. Sarah Tedeschi Dr. Jack Cush (moderator)

QD307: Senior Year Gout https://youtu.be/_TGgcdQsfic QD308: Allopurinol for All Gout? Not Quite https://youtu.be/JAwUb-hqeFs QD309: Cellulitis Paradoxes https://youtu.be/j3feySk5wQo QD310: Gout: Is it the Journey or the Destination? https://youtu.be/1J-ZrbaGsD8 QD311: When There's Doubt in Gout https://youtu.be/DpAevfq7Oo0
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month. Visit https://rheumnow.com/campaign/gout-campaign-july-2026 for all of our coverage throughout July.

Gout Journal Club will examine two influential publications: 1. "Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients with Gout" (Cipolletta et al., JAMA Internal Medicine, 2026) and 2. "Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"(Wang et al., JAMA Internal Medicine, 2025). Together, these studies provide new evidence supporting treat-to-target urate-lowering strategies and their potential impact on cardiovascular and renal outcomes. Panelists: Abhishek Abhishek, MD, PhD, MBBS, FRCP Zeqin Wen, MD Jie Wei, PhD Jack Cush, MD (moderator) Beyond reviewing the evidence, our expert panel will tackle the practical questions rheumatologists face every day.

In August, Dr. Christina Charles-Schoeman and Dr. Manish Jain will return with a new episode exploring the latest clinical data on RA treatment after TNFi failure. Before that episode drops, revisit their 2025 conversation on disease control, real-world data, and guidelines that inform clinical decision-making after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.